Screening for Hereditary Breast Cancer

Seminars in Oncology

Volumn 34, Issue 5, 2007, Pages 392-400

  Dent, Rebecca ^a   Warner, Ellen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER SCREENING; CANCER STAGING; CARCINOMA IN SITU; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; FALSE POSITIVE RESULT; FAMILIAL CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; PATIENT COUNSELING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SURVIVAL TIME; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION;

EID: 34848922073     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.07.002     Document Type: Article

References (65)

1. Botkin J.R., Smith K.R., Croyle R.T., et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118 (2003) 201-209
2. Schwartz M.D., Lerman C., Brogan B., et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22 (2004) 1823-1829
3. Ries L.A.G., Harkins D., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2003 (2006), National Cancer Institute, Bethesda, MD
4. Wooster R., and Weber B.L. Genomic medicine: Breast and ovarian cancer. N Engl J Med 348 (2003) 2339-2347
5. Narod S.A., Brunet J.S., Ghadirian P., et al., Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356 (2000) 1876-1881
6. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP P-1) Breast Cancer Prevention Trial. JAMA 286 (2001) 2251-2256
7. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (2002) 1609-1615
8. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 616-1622
9. Tabar L., Fagerberg G., Day N.E., et al. Breast cancer treatment and natural history: New insights from results of screening. Lancet 339 (1992) 412-414
10. Brekelmans C.T.M., Seynaeve C., Bartels C.C.M., et al. Surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19 (2001) 924-930
11. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (2002) 1260-1268
12. Vasen H.F.A., Tesfay E., Bonnstra H., et al. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 41 (2004) 549-554
13. Komenaka I.K., Ditkoff B., Joseph K., et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 100 (2004) 2079-2083
14. Wolfe J.N. Breast parenchymal patterns and their changes with age. Radiology 121 (1976) 545-552
15. Carney P.A., Miglioretti D.L., Yankaskas B.C., et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138 (2003) 168-175
16. Tabar L., Duffy S.W., Vitak B., et al. The natural history of breast carcinoma: What have we learned from screening?. Cancer 86 (1999) 449-462
17. Feig S.A. Screening mammography controversies: Resolved, partly resolved, unresolved. Breast J 11 suppl 1 (2005) S3-S6
18. Weaver D.L., Rosenberg R.D., Barlow W.E., et al. Pathologic findings from the Breast Cancer Surveillance Consortium: Population-based outcomes in women undergoing biopsy after screening mammography. Cancer 106 (2006) 732-742
19. Tilanus-Linthorst M.M.A., Kriege M., Boetes C., et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 41 (2005) 1610-1617
20. Peer P.G., van Dijck J.A., Hendriks J.H., et al. Age-dependent growth rate of primary breast cancer. Cancer 71 (1993) 3547-3551
21. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 (1998) 1138-1145
22. Marcus J.N., Watson P., Page D.L., et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77 (1996) 697-709
23. Chang J., Yang W.T., and Choo H.F. Mammography in Asian patients with BRCA1 mutations. Lancet 353 (1999) 2070-2071 (letter)
24. Goffin J., Chappuis P.O., Wong N., et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93 (2001) 1754-1755 (letter)
25. Tilanus-Linthorst M., Verhoog L., Obdeijn I.-M., et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102 (2002) 91-95
26. Kolb T.M., Lichy J., and Newhouse J.H. Comparison of the performance of screening mammography, physical examination, and breast ultrasound and evaluation of factors that influence them: An analysis of 27, 825 patient evaluations. Radiology 225 (2002) 165-175
27. Berg W.A. Rationale for a trial of screening breast ultrasound: American College of Radiology Imaging Network (ACRIN) 6666. AJR Am J Roentgenol 180 (2006) 1225-1228
28. Eisinger F., Bressac B., Castaigne D., et al. Identification and management of hereditary breast-ovarian cancers (2004 update). Pathol Biol 54 (2006) 230-250
29. Strich G., Hagan P.L., Gerber K.H., et al. Tissue distribution and magnetic resonance spin lattice relaxation effect of gadolinium-DTPA. Radiology 154 (1985) 723-726
30. Cohen E.K., Leonhardt C.M., Shumak R.S., et al. Magnetic resonance imaging in potential postsurgical recurrence of breast cancer: pitfalls and limitations. Can Assoc Radiol J 47 (1996) 171-176
31. Bluemke D., Gatsonis C., Chen M., et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 292 (2004) 2735-2742
32. Orel S.G., and Schnall M.D. MR imaging of the breast for the detection, diagnosis and staging of breast cancer. Radiology 220 (2001) 13-30
33. Morris E.A., Liberman L., Ballon D.J., et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 181 (2003) 619-626
34. Kuhl C.K., Schrading S., Leutner C.C., et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women with high familial risk for breast cancer. J Clin Oncol 23 (2005) 8469-8476
35. Warner E., Plewes D.B., Hill K.A., et al. Surveillance of BRCA1 and BRCA2 mutations carriers with magnetic resonance imaging, ultrasound, mammography and clinical breast examination. JAMA 292 (2004) 1317-1325
36. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (2004) 427-437
37. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 365 (2005) 1769-1778
38. Lehman C.D., Blume J.D., Weatherall P., et al. Screening women at high risk of breast cancer with mammography and magnetic resonance imaging. Cancer 103 (2005) 1898-1905
39. Podo F., Sardanelli F., Canese R., et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 21 (2002) 115-124
40. Kriege M., Brekelmans C.T.M., Boetes C., et al. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer 106 (2006) 2318-2326
41. Sardanelli F., and Podo F. Breast MR imaging in women at high risk of breast cancer. Is something changing in early breast cancer detection?. Eur Radiol 17 (2007) 873-887
42. Warner E., Plewes D., Hill K., et al. Effect of age and temporal patterns over 5 years in a magnetic resonance imaging-based breast surveillance study for BRCA mutation carriers. Proc Am Soc Clin Oncol 23 (2004) 831 (abstr)
43. Bigenwald R., Warner E., Gunasekara K., et al. Is mammography adequate for screening BRCA mutation carriers with low breast density?. Proc Am Soc Clin Oncol 24 (2006) 544s (abstr)
44. Kriege M., Brekelmans C.T.M., Obdeijn I.M., et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat 100 (2006) 109-119
45. Warner E., Causer P., Hill K., et al. MRI surveillance downstages invasive cancer (IC) to DCIS in women at high risk for hereditary breast cancer. Breast Cancer Res Treat 94 suppl 1 (2005) S2505 Proceedings of the 28th Annual San Antonio Breast Cancer Symposium, (abstr)
46. Warren R.M., Pointon L., Thompson D., et al. Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. Radiology 236 (2005) 779-788
47. Menell J.H., Morris E.A., Dershaw D.D., et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 11 (2005) 382-390
48. Plevritis S.K., Kurian A.W., Sigal B.M., et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295 (2006) 2374-2384
49. Stout N.K., Rosenberg M.A., Trentham-Dietz A., et al. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 98 (2006) 774-782
50. Greibsch I., Brown J., Boggis C., et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs. xray mammography of women at a high familial risk of breast cancer. Br J Cancer 95 (2006) 801-810
51. Cullen J., Schwartz M.D., Lawrence W.F., et al. Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol 22 (2004) 943-952
52. Anderson J., Walker L.G., Leach M.O., et al. Magnetic resonance imaging: An acceptable way of screening women with a family history of breast cancer (2004) Proceedings of the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-10, (abstr)
53. Van Dooren S., Seynaive C., Rijnsberger A.J., et al. Exploring the course of psychological distress around two successive control visits in women at hereditary risk for breast cancer. Eur J Cancer 41 (2005) 1416-1425
54. Warner E. Intensive radiologic surveillance: A focus on the psychological issues. Ann Oncology 15 suppl 1 (2004) 143-147
55. Hill K.A., Warner E., Esplen M.J., et al. Distress and breast cancer anxiety among women with BRCA mutations participating in a breast screening study (2006) Presented at the 8th World Congress of Psycho-oncology, Venice, Italy, October 18-21
56. NCCN Practice Guidelines in Oncology: Hereditary Breast and Ovarian Cancer Management (2006). http://www.nccn.com/physician_gls/index.html Vol. 1, www.nccn.com/physician_gls/index.html (accessed November 20, 2006)
57. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57 (2007) 75-89
58. Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary, and tertiary care. National Collaborating Centre for Primary Care. Update July 2006. http://www.nice.org
59. Lehman C.D., and Schnall M.D. Imaging in breast cancer: Magnetic resonance imaging. Breast Cancer Res 7 (2005) 215-219
60. Daniel B.L., Birdwell R.L., Butts K., et al. Freehand iMRI-guided large guage core needle biopsy: A new minimally invasive technique for diagnosis of enhancing breast lesions. J Magn Reson Imaging 13 (2001) 896-902
61. Kuhl C.K., Morakkabati N., Leutner C.C., et al. MR Imaging-guided large-core (14 guage) needle biopsy of small lesions visible at breast MRI imaging alone. Radiology 220 (2001) 31-39
62. Katz-Brull R., Lavin P.T., and Lenkinsk R.E. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 94 (2002) 1197-1203
63. Dobbins III J.T., and Godfrey D.J. Digital x-ray tomosynthesis: Current state of the art and clinical potential. Phys Med Biol 48 (2003) R65-R106
64. Jong R.A., Yaffe M.J., Skarpathiotakis M., et al. Contrast-enhanced digital mammography: Initial clinical experience. Radiology 228 (2003) 842-850
65. Hill K., and Warner E. Are clinical breast examination and breast self-examination a source of stress or relief for BRCA mutation carriers?. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio TX, December 13-15 (2006) (abstr 4036)